Ultragenyx Pharmaceutical (MEX:RARE) Retained Earnings: MXN-85,060 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RARE Ultragenyx Pharmaceutical Inc MEX:RARE
69 GF Score
Price MXN1,150.56
GF Value MXN2,020.93
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Retained Earnings?

Ultragenyx Pharmaceutical MEX:RARE 69 Retained Earnings is MXN-85,060 Mil as of Mar. 2026. GuruFocus rates MEX:RARE with a GF Score™ of 69/100 and a GF Value™ of MXN2,020.93. The stock has 5 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Ultragenyx Pharmaceutical's retained earnings for the quarter that ended in Mar. 2026 was MXN-85,060 Mil.

Ultragenyx Pharmaceutical's quarterly retained earnings declined from Sep. 2025 (MXN-80,775 Mil) to Dec. 2025 (MXN-81,602 Mil) and declined from Dec. 2025 (MXN-81,602 Mil) to Mar. 2026 (MXN-85,060 Mil).

Ultragenyx Pharmaceutical's annual retained earnings declined from Dec. 2023 (MXN-57,503 Mil) to Dec. 2024 (MXN-82,526 Mil) but then increased from Dec. 2024 (MXN-82,526 Mil) to Dec. 2025 (MXN-81,602 Mil).


Ultragenyx Pharmaceutical  (MEX:RARE) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Ultragenyx Pharmaceutical Retained Earnings Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical Retained Earnings Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42,537.85 -54,218.81 -57,503.00 -82,526.01 -81,601.83

Ultragenyx Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -84,040.73 -79,513.36 -80,774.80 -81,601.83 -85,060.25
MEX:RARE
69GF Score
Ultragenyx Pharmaceutical Inc MEX:RARE
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ultragenyx Pharmaceutical Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of MXN-85,060 Mil mean?
Ultragenyx Pharmaceutical (MEX:RARE) has a Retained Earnings of MXN-85,060 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Ultragenyx Pharmaceutical and its competitors.
Is Ultragenyx Pharmaceutical's Retained Earnings too high?
Ultragenyx Pharmaceutical's current Retained Earnings is MXN-85,060 Mil. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Retained Earnings compare to VERA and IRON?
Ultragenyx Pharmaceutical's Retained Earnings of MXN-85,060 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Ultragenyx Pharmaceutical and its competitors. Ultragenyx Pharmaceutical's current Retained Earnings is MXN-85,060 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Ultragenyx Pharmaceutical (MEX:RARE) has a current Retained Earnings of MXN-85,060 Mil. The stock's GF Value™ is MXN2,020.93, compared to a current price of MXN1,150.56 — trading 43.1% below its estimated fair value. The current Retained Earnings is MXN-85,060 Mil. Ultragenyx Pharmaceutical's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current Retained Earnings is MXN-85,060 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of MXN1,150.56 is trading 43.1% below its estimated GF Value™ of MXN2,020.93.

Key valuation signals for MEX:RARE:

  • Retained Earnings: MXN-85,060 Mil
  • GF Value™: MXN2,020.93 vs. price of MXN1,150.56 (43.1% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
69GF Score

Get the complete analysis for MEX:RARE

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.56
Price
MXN2,020.93
GF Value